Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 8Specimen Handling 5Magnetic Resonance Spectroscopy 5pembrolizumab 3olaparib 2fludarabine 2cabozantinib 2X-Rays 2Phantoms, Imaging 2Cyclophosphamide 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 2repotrectinib 1peposertib 1pazopanib 1lenvatinib 1fludarabine phosphate 1entrectinib 1belinostat 1aldesleukin 1Yttrium-90 1Tomography, X-Ray Computed 1Tomography, Emission-Computed, Single-Photon 1Temozolomide 1Single Photon Emission Computed Tomography Computed Tomography 1Salts 1Positron Emission Tomography Computed Tomography 1PT-100 dipeptide 1Octreotide 1Nivolumab 1Introns 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × Tomography, Emission-Computed, Single-Photon × 30 days × Clear all
NCT06122610 2026-05-15

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

University of Wisconsin, Madison

Phase 1 Recruiting
10 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡